Genentech and OSI to pay $67m to resolve False Claims Act allegations for Tarceva
US-based pharmaceutical companies Genentech and OSI Pharmaceuticals will pay $67m in order to resolve False Claims Act allegations regarding misleading statements made about the effectiveness of Tarceva for treating non-small cell lung cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Tarceva